Gwen Melincoff

Gwen Melincoff is an accomplished professional with extensive experience in the biopharmaceutical industry. Currently serving on the Board of Directors for Gain Therapeutics, Protalix Biotherapeutics, Collegium Pharmaceutical, Inc., and Soleno Therapeutics, Melincoff also acts as Chief Business Advisor at HighTide Therapeutics and Managing Director at Gemini Advisors, a consultancy focusing on business development and corporate strategy. Additionally, Melincoff has held advisory positions with Verge Genomics and was an Investment Committee Member at Hatch Biofund Management. Education includes an MS in Management with a focus on Health Care from Penn State Great Valley, complemented by a BS in Biology from The George Washington University.